Chemours (CC) Provides Update on Internal Review
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Trump Media and TAE Technologies file S-4 for all-stock merger
Chemours Provides Update on Internal Review
March 6, 2024 8:30 PM ESTWILMINGTON, Del.--(BUSINESS WIRE)-- As previously disclosed, the Audit Committee of the Board of Directors of The Chemours Company (Chemours or the Company) (NYSE: CC), with the assistance of independent outside counsel, has been overseeing an internal review. The review relates to an anonymous report made to the Chemours Ethics Hotline regarding the matters described below. A substantially complete report of the findings of the internal review was delivered to the full Board on March 5, 2024.
Chair Dawn Farrell said The Chemours Board of Directors takes these issues very seriously and appreciates the diligent... More
